Beyond the intention-to treat effect: Per-protocol effects in randomized trials

Similar documents
Generalizing the right question, which is?

Per-Protocol Analyses of Pragmatic Trials

ICH E9(R1) Technical Document. Estimands and Sensitivity Analysis in Clinical Trials STEP I TECHNICAL DOCUMENT TABLE OF CONTENTS

Treatment changes in cancer clinical trials: design and analysis

A (Constructive/Provocative) Critique of the ICH E9 Addendum

Estimands and Sensitivity Analysis in Clinical Trials E9(R1)

Estimands in klinischen Studien: was ist das und geht mich das was an?

Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies

Transmission to CHMP July Adoption by CHMP for release for consultation 20 July Start of consultation 31 August 2017

Randomized Experiments with Noncompliance. David Madigan

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017

Complier Average Causal Effect (CACE)

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials

Estimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA

EU regulatory concerns about missing data: Issues of interpretation and considerations for addressing the problem. Prof. Dr.

Strategies for handling missing data in randomised trials

State of the art pharmacoepidemiological study designs for post-approval risk assessment

The Logic of Causal Inference. Uwe Siebert, MD, MPH, MSc, ScD

How the ICH E9 addendum around estimands may impact our clinical trials

Comparison And Application Of Methods To Address Confounding By Indication In Non- Randomized Clinical Studies

Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials

Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis

Non-inferiority trials and switch from non-inferiority to superiority. D Costagliola U 943 INSERM and UPMC Paris 06

Estimands and Their Role in Clinical Trials

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014

The ROBINS-I tool is reproduced from riskofbias.info with the permission of the authors. The tool should not be modified for use.

GRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018

ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis

Declaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018

GLOSSARY OF GENERAL TERMS

The RoB 2.0 tool (individually randomized, cross-over trials)

Evidence Based Medicine

Fundamental Clinical Trial Design

Real-world data in pragmatic trials

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Missing data in clinical trials: a data interpretation problem with statistical solutions?

Methodological aspects of non-inferiority and equivalence trials

Accounting for treatment switching/discontinuation in comparative effectiveness studies

Supplement 2. Use of Directed Acyclic Graphs (DAGs)

Estimands for time to event endpoints in oncology and beyond

Data and Safety Monitoring in Pragmatic Clinical Trials. Susan S. Ellenberg, PhD Greg Simon, MD, MPH Jeremy Sugarman, MD, MPH, MA

The role of Randomized Controlled Trials

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean

Confounding by indication developments in matching, and instrumental variable methods. Richard Grieve London School of Hygiene and Tropical Medicine

Brief introduction to instrumental variables. IV Workshop, Bristol, Miguel A. Hernán Department of Epidemiology Harvard School of Public Health

The (mis)use of treatment switching adjustment methods in health technology assessment busting some myths!

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.

Critical Appraisal Series

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial

Title:Bounding the Per-Protocol Effect in Randomized Trials: An Application to Colorectal Cancer Screening

AVOIDING BIAS AND RANDOM ERROR IN DATA ANALYSIS

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

A Framework for Patient-Centered Outcomes Research

Glossary of Practical Epidemiology Concepts

Is There An Association?

Welcome to this third module in a three-part series focused on epidemiologic measures of association and impact.

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial

Structural Approach to Bias in Meta-analyses

MATH& 146 Lesson 6. Section 1.5 Experiments

EBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University

Study Design. Study design. Patrick Breheny. January 23. Patrick Breheny Introduction to Biostatistics (171:161) 1/34

Estimating the impact of community-level interventions: The SEARCH Trial and HIV Prevention in Sub-Saharan Africa

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

Careful with Causal Inference

Biostatistics 3. Developed by Pfizer. March 2018

Estimands in oncology

Collecting Data Example: Does aspirin prevent heart attacks?

Variables Research involves trying to determine the relationship between two or more variables.

Sampling Controlled experiments Summary. Study design. Patrick Breheny. January 22. Patrick Breheny Introduction to Biostatistics (BIOS 4120) 1/34

Issues to Consider in the Design of Randomized Controlled Trials

16:35 17:20 Alexander Luedtke (Fred Hutchinson Cancer Research Center)

Comparisons of Dynamic Treatment Regimes using Observational Data

Supplementary Online Content

Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database

Right Answers, Wrong Ques2ons. Ralph I Horwitz

Research Methodology. Characteristics of Observations. Variables 10/18/2016. Week Most important know what is being observed.

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT

Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators

Estimating Direct Effects of New HIV Prevention Methods. Focus: the MIRA Trial

Epidemiological study design. Paul Pharoah Department of Public Health and Primary Care

Study Designs in Epidemiology

Adjusting overall survival for treatment switch

Delfini Evidence Tool Kit

Sensitivity Analysis in Observational Research: Introducing the E-value

About Reading Scientific Studies

Clinical Epidemiology I: Deciding on Appropriate Therapy

A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE

Systematic Reviews and Meta- Analysis in Kidney Transplantation

PhD Course in Biostatistics

Evidence Based Practice

Noninferiority Clinical Trials

Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs

Understanding noninferiority trials

Causal versus Casual Inference

Instrumental Variables Estimation: An Introduction

C2 Training: August 2010

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

Transcription:

Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS

Intention-to-treat analysis (estimator) estimates intention-to-treat effect (estimand) Intention-to-treat effect The effect of being assigned to a treatment strategy, regardless of treatment received, in a particular setting Intention-to-treat effects are agnostic about postrandomization decisions Changes in studied treatment: discontinuation, switching Use of concomitant therapies prohibited by the study protocol etc. Hernán - Beyond the intention-to-treat 2

Demystifying intention-to-treat effects: Not necessarily preserve the null Consider a non-blinded trial The ITT effect may not be null even if treatment has a null effect on the outcome Patients and doctors may just alter their behavior in ways that affect their outcome Most pragmatic trials are not blinded Hernán - Beyond the intention-to-treat 3

Demystifying intention-to-treat effects: Not necessarily biased towards the null When the treatment effect is not monotonic not in the same direction for all individuals Trial of active treatment vs placebo 30% of the individuals assigned to treatment did not adhere to treatment direction of the effect in adherers opposite to that in non-adherers An ITT analysis may misleadingly indicate a beneficial effect of the less efficacious treatment Hernán - Beyond the intention-to-treat 4

Demystifying intention-to-treat effects: Not necessarily biased towards the null Even if the treatment effect is monotonic Trial of 2 active treatments with differential adherence due to a mild, easily palliated side effect An ITT analysis may misleadingly indicate a beneficial effect of the less efficacious treatment Many pragmatic trials are head-to-head trials Hernán - Beyond the intention-to-treat 5

Demystifying intention-to-treat effects: Bias towards the null is often undesirable Safety trials Non-inferiority trials In these trials, a conservative ITT analysis is statistical malpractice A trial designed to quantify harm and whose protocol foresees only an ITT analysis could be referred to as a randomized cynical trial Many pragmatic trials are for safety, non-inferiority Hernán - Beyond the intention-to-treat 6

Demystifying intention-to-treat effects: Not necessarily a measure of effectiveness Degree of adherence outside the trial may change drastically after doctors and patients learn of the trial s findings Actual effectiveness in the community may differ from ITT effect estimate from trial Hernán - Beyond the intention-to-treat 7

Demystifying intention-to-treat effects: Not of primary interest for doctors and patients For example, a couple trying to decide whether to use a contraceptive method would want to know the effectiveness of the method when used as indicated not the estimated effectiveness in a population in which, say, 40% of couples failed to use the method properly That is, not the ITT effect Pragmatic trials are designed to guide clinical decisions by patients and doctors Hernán - Beyond the intention-to-treat 8

Need a complement to the ITT effect: An effect measure (an estimand) not affected by the degree of adherence usable in safety, noninferiority trials clinically relevant, patient-centered Per-protocol effect: the effect of implementing the treatment strategies as described in the protocol Hernán - Beyond the intention-to-treat 9

A big difference between ITT effect and per-protocol effect We have a universally accepted way of estimating ITT effects ITT analysis Almost uncontroversial We don t have a universally accepted way of estimating per-protocol effects There are many types of per-protocol analysis Including the commonly used, unadjusted, naïve perprotocol analysis Hernán - Beyond the intention-to-treat 10

Intention-to-treat effect Analysis plan Simple Compare outcome distribution between group assigned to different strategies Regardless of whether individuals actually followed the strategies Often overlooked problem: ITT analysis cannot be conducted if there are losses to follow-up Potential selection bias due to informative censoring Hernán - Beyond the intention-to-treat 11

Intention-to-treat effect Analysis plan Estimating ITT effect requires adjustment for selection bias due to loss to follow-up Adjustment for baseline and post-baseline covariates Little et al, NEJM 2012 In fact, intention-to-treat effect is more precisely defined as the effect of being assigned to a strategy, regardless of strategy received, while staying under follow-up throughout the study Hernán - Beyond the intention-to-treat 12

Per-protocol effect Analysis plan Not so simple Treatment decisions after baseline are not randomized Potential post-randomization confounding and selection bias Example In a statins trial, statin use after baseline may depend on post-baseline cholesterol levels; dropout may depend on side effects and prognosis Hernán - Beyond the intention-to-treat 13

Per-protocol effect Analysis plan Estimating the per-protocol effect requires adjustment for confounding Adjustment for baseline and post-baseline covariates In addition to adjustment for selection bias same as for ITT effects Hernán - Beyond the intention-to-treat 14

Effects (estimands) vs. analyses (estimators) The elephant in the room Typical ITT and per-protocol analyses adjust for neither pre- nor post-randomization variables Potentially biased estimates of ITT and per protocol effects This is a problem for all randomized trials because treatment choices and participation decisions after baseline are not randomly assigned But especially for pragmatic trials with lots of room for non-adherence and loss to follow-up Hernán - Beyond the intention-to-treat 15

A pragmatic randomized trial is a follow-up study with baseline randomization Analysis methods to adjust for post-baseline confounding and selection bias are the same methods used for observational follow-up studies Adjustment for post-randomization (time-varying) variables require special techniques Inverse probability (IP) weighting, g-formula, etc Developed by Robins et al since 1986 Instrumental variable estimation Hernán - Beyond the intention-to-treat 16

Case study Hormone therapy and breast cancer Question What is the effect of postmenopausal hormone therapy on risk of breast cancer in postmenopausal women? Data A Women s Health Initiative randomized trial ~16,000 postmenopausal U.S. women Toh et al. Epidemiology 2010; 21:528-539 Hernán - Beyond the intention-to-treat 17

Effect of hormone therapy, what effect? Effect of assignment to hormone therapy under the study s conditions? Intention-to-treat effect Effect of hormone therapy use as instructed by the study s protocol? Per-protocol effect BOTH They answer different questions Hernán - Beyond the intention-to-treat 18

Methodological challenges for per protocol effect Time-varying treatment Women may not adhere to their assigned treatment (hormone therapy or placebo) Time-varying confounders Use of hormone therapy depends on age, BMI, symptoms may be affected by prior treatment Also better to estimate absolute risks Appropriately adjusted survival curves Not only hazard ratios Hernán - Beyond the intention-to-treat 19

Methodological approach to estimate per protocol effect Estimate IP weights to adjust for time-varying confounding Need data on post-randomization variables Estimate IP weighted hazards model to estimate Hazard ratios Survival (or cumulative incidence) Compare survival curves for continuous treatment vs. no treatment Standardize curves to baseline variables Hernán - Beyond the intention-to-treat 20

Hazard ratio of breast cancer Hormone therapy vs. placebo Intention to treat effect estimate 1.25 (1.01, 1.54) Per protocol effect estimate 1.68 (1.24 to 2.28) Suppose you are a woman considering initiation of hormone therapy and who plans to take it as instructed by your doctor Which hazard ratio do you want? Hernán - Beyond the intention-to-treat 21

Validity of per-protocol effect estimates Relies on adjustment for post-randomization confounding and selection bias via the same analytic methods and under the same untestable assumptions that we usually reserve for observational studies Hernán - Beyond the intention-to-treat 22

Review: Classification of treatment strategies according to their time course Point interventions Intervention occurs at a single time Examples: one-dose vaccination, short-lived traumatic event, surgery Sustained strategies Interventions occur at several times Examples: medical treatments, lifestyle, environmental exposures Hernán - Beyond the intention-to-treat 23

Choice of statistical adjustment method depends on type of strategies Comparison of strategies involving point interventions only All methods work if all confounders are measured or the instrumental variable conditions hold Comparison of sustained strategies Generally only g-methods work Developed by Robins and collaborators since 1986 Hernán - Beyond the intention-to-treat 24

Per-protocol effect is generally a contrast of sustained (dynamic) treatment strategies Not a comparison of continuous treatment A vs. continuous treatment B But a comparison of strategies of the sort start taking A, continue taking A until toxicity arises, then switch to B Implications for definition of per-protocol effect definition of adherence data collection requirements: need post-randomization data on treatment adherence and (time-varying) confounders Hernán - Beyond the intention-to-treat 25

Conclusions (I) There are good reasons for ITT analyses to remain the primary analyses of many randomized trials Also good reasons for appropriately adjusted perprotocol analyses as an integral component of randomized trial analysis especially relevant to patients and clinicians can also be used by modelers and healthcare planners to estimate an upper bound of the impact of changes in recommendations Hernán - Beyond the intention-to-treat 26

Conclusions (II) The validity of per-protocol effects requires Explicit definition of per-protocol effect and adherence A priori specification of the statistical plan for the perprotocol analysis High-quality data on adherence and prognostic factors Appropriate adjustment methods These requirements necessitate changes in the way we design and conduct trials Hernán - Beyond the intention-to-treat 27

Thank you (more on Twitter @_MiguelHernan) This work is supported by PCORI ME-1503-28119 Additional readings Hernán MA, Hernández-Díaz S. Beyond the intention to treat in comparative effectiveness research. Clinical Trials 2012; 9(1):48-55. Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed like observational studies. Annals of Internal Medicine 2013; 159(8): 560-562 Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. International Journal of Biostatistics 2008; 4(1): Article 22 Hernán - Beyond the intention-to-treat 28